WEKO3
アイテム
Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients
http://hdl.handle.net/10069/0002002408
http://hdl.handle.net/10069/0002002408d5365080-19db-467f-acd2-d60a8baf946f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KISYK46_Kurushima.pdf (1 MB)
|
|
| アイテムタイプ | 学位論文 / Thesis or Dissertation(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-06-12 | |||||||
| タイトル | ||||||||
| タイトル | Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients | |||||||
| 言語 | en | |||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | rheumatoid arthritis | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | interstitial lung disease | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | RA-ILD | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | JAK inhibitors | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | methotrexate | |||||||
| キーワード | ||||||||
| 言語 | en | |||||||
| 主題Scheme | Other | |||||||
| 主題 | epithelial-mesenchymal transition | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||
| 資源タイプ | doctoral thesis | |||||||
| アクセス権 | ||||||||
| アクセス権 | open access | |||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
| 著者 |
來留島, 章太
× 來留島, 章太
|
|||||||
| 著者別名 | ||||||||
| 姓名 | Kurushima, Shota | |||||||
| 言語 | en | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Objectives: Little is known about how various treatments impact the progression of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. Here, we compared ILD progression in RA patients treated with Janus kinase inhibitors (JAKi) or biological disease-modifying anti-rheumatic drugs (bDMARDs). In vitro experiments were also performed to evaluate the potential effects of the drugs on epithelial–mesenchymal transition (EMT), a key event in pulmonary fibrosis. Methods: This retrospective study included 93 RA-ILD patients who initiated treatment with JAKi, tumour necrosis factor inhibitors (TNFi), or abatacept between 2017 and 2020. Worsening ILD was quantified by changes in chest computed tomography (CT) scans between baseline and follow-up (mean 14 months, range 6–51 months). Response to treatment was evaluated using Disease Activity Score-28 with erythrocyte sedimentation rate (DAS28-ESR). Expression of the EMT marker N-cadherin in A549 lung cells was assessed by western blotting. Results and discussion: Worsening ILD was detected in 19.4% (7/36), 16.7% (5/30), and 22.2% (6/27) of patients treated with JAKi, abatacept, and TNFi, respectively. Multivariate analysis identified female gender (P=0.043) and >10% fibrotic lesions (P=0.015) as significant predictors of worsening ILD. DAS28-ESR-based non-responder status was also significantly associated with worsening ILD (P=0.0085). In vitro, combination treatment with methotrexate and baricitinib significantly impeded EMT progression. Worsening ILD was associated with more extensive fibrotic lesions at baseline and female gender in RA patients treated with JAKi or bDMARDs. JAKi and methotrexate co-treatment may prove beneficial in modifying key events underlying the pathogenesis of RA-ILD. | |||||||
| 言語 | en | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | 長崎大学学位論文 学位記番号:共博(医歯薬)甲第46号 学位授与年月日:令和7年3月5日 | |||||||
| 言語 | ja | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Author: Shota Kurushima, Tomohiro Koga, Masataka Umeda, Naoki Iwamoto, Ritsuko Miyashita, Takatomo Tokito, Daisuke Okuno, Hirokazu Yura, Hiroshi Ishimoto, Takashi Kido, Noriho Sakamoto, Yukitaka Ueki, Hiroshi Mukae and Atsushi Kawakami | |||||||
| 言語 | en | |||||||
| 内容記述 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Citation: Frontiers in Immunology, 15, art. no. 1501146; 2024 | |||||||
| 言語 | en | |||||||
| 書誌情報 |
en : Frontiers in Immunology 巻 15, p. art. no. 1501146, 発行日 2025-03-05 |
|||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 16643224 | |||||||
| DOI | ||||||||
| 関連タイプ | isIdenticalTo | |||||||
| 識別子タイプ | DOI | |||||||
| 関連識別子 | 10.3389/fimmu.2024.1501146 | |||||||
| 権利 | ||||||||
| 権利情報 | © 2024 Kurushima, Koga, Umeda, Iwamoto, Miyashita, Tokito, Okuno, Yura, Ishimoto, Kido, Sakamoto, Ueki, Mukae and Kawakami. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | |||||||
| 言語 | en | |||||||
| 著者版フラグ | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| その他のタイトル | ||||||||
| その他のタイトル | 関節リウマチ患者の間質性肺疾患に対してヤヌスキナーゼ阻害薬やメトトレキサートが与える影響 | |||||||
| 言語 | ja | |||||||
| 出版者 | ||||||||
| 出版者 | Frontiers Media S.A. | |||||||
| 言語 | en | |||||||
| 関係URI | ||||||||
| 識別子タイプ | HDL | |||||||
| 関連識別子 | http://hdl.handle.net/10069/0002002345 | |||||||
| 学位名 | ||||||||
| 学位名 | 博士(医学) | |||||||
| 言語 | ja | |||||||
| 学位授与機関 | ||||||||
| 学位授与機関識別子Scheme | kakenhi | |||||||
| 学位授与機関識別子 | 17301 | |||||||
| 学位授与機関名 | Nagasaki University (長崎大学) | |||||||
| 言語 | en | |||||||
| 学位授与年月日 | ||||||||
| 学位授与年月日 | 2025-03-05 | |||||||
| 学位授与番号 | ||||||||
| 学位授与番号 | 甲共医歯薬第46号 | |||||||
| 学位の種類 | ||||||||
| 言語 | ja | |||||||
| 値 | 課程博士 | |||||||
| 引用 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | Nagasaki University (長崎大学), 博士(医学) (2025-03-05) | |||||||
